8 April 2025
Maxwellia appoints Alexandra Trehane as Chief Operating Officer as company sets to scale
Alderley Park, UK – April 7 2025 – Maxwellia, the pioneering consumer healthcare company dedicated to widening access to medicines, is pleased to announce the appointment of Alexandra Trehane as Chief Operating Officer. Alexandra brings extensive experience in operations...
24 March 2025
Oxford BioTherapeutics enters into a strategic collaboration with Roche to discover novel targets for antibody-based therapeutics for the treatment of cancer
• Collaboration leverages OBT’s proprietary OGAP®-Verify discovery platform and Roche’s drug development expertise to advance multiple selected novel oncology targets … • OBT to receive up to US$36 million upfront payments and may be eligible to receive milestone payments...
20 March 2025
GM&C Life Sciences Fund announces £100m+ in matched private sector investment for Greater Manchester, Cheshire and Warrington
Alderley Park, UK, 19th March 2025 – The GM&C Life Sciences Fund, managed by Catapult Ventures, has announced that to date it has leveraged over £100m in private sector life science co-investment. Managed by Catapult Ventures, the GM&C Life Sciences Fund is a seed and...
26 February 2025
Monument Therapeutics secures £850k to advance breakthrough schizophrenia treatment
Manchester, 25th February 2025 — Monument Therapeutics, an innovative neuroscience company applying digital biomarkers to psychiatric drug development, has secured £850k in further funding led by ACF Investors, with participation from Wren Capital, o2h Ventures, and angel...
25 February 2025
Infex signs exclusive license agreement with Venus Remedies Ltd to advance MET-X through clinical development and commercialisation in India
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives specialist, announces that it has signed an exclusive license agreement for the Indian market (the “Agreement”) with Venus Remedies Ltd (NSE: VENUSREM BSE: 526953) (“Venus Remedies”), an Indian...
18 February 2025
Infex and Justus-Liebig-University Giessen awarded £1 million grant from PACE
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives specialist, announces that in collaboration with Justus-Liebig-University Giessen (“JLU”), Germany it has been awarded a £1 million grant from PACE (Pathways to Antimicrobial Clinical Efficacy), to...
17 February 2025
Manchester medtech company Pill Connect secures new investment to transform clinical trials
A medtech company that has created a unique digital device to track whether patients are taking their medicine correctly has secured funding from the GMC Life Sciences Fund By Praetura, and through NPIF II – Praetura Equity Finance, which is managed by Praetura Ventures as part...
12 February 2025
AgTech startup CroBio raises €850k to reshape agriculture through enhanced microbes
Cheshire-based CroBio, an AgTech startup on a mission to reshape the future of agriculture by harnessing the power of enhanced microbes, announced €805k in new funding to enhance their living soil amendment, a technology designed to improve nutrient retention, water retention...
21 January 2025
Monument Therapeutics announces grant of Chinese patent in support of its MT1988 cognitive impairment associated with schizophrenia program.
Manchester, UK, 21 January 2025 - Monument Therapeutics, a stratified medicine company developing novel treatments for areas of high unmet need in psychiatry and neurology, today announced that the China National Intellectual Property Administration (“CNIPA”) has granted Chinese...
14 January 2025
Monument Therapeutics announces grant of Japanese patent in support of its MT1988 cognitive impairment associated with schizophrenia program
Manchester, UK, 14 January 2025 - Monument Therapeutics, a stratified medicine company developing novel treatments for areas of high unmet need in psychiatry and neurology, today announced that the Japan Patent Office (“JPO”) has granted Japanese patent 7570345, in support of...